Preclinical Characterization of XL092, a Novel Receptor Tyrosine Kinase Inhibitor of MET, VEGFR2, AXL, and MER.
Hsu J, Chong C, Serrill J, Goon L, Balayan J, Johnson EN, Lorenzana G, Wu S, Leong KG, Yun TJ, Wang Y, Jiang F, Bannen L, Lamb P, Xu W, Yu P.
Hsu J, et al. Among authors: leong kg.
Mol Cancer Ther. 2023 Feb 1;22(2):179-191. doi: 10.1158/1535-7163.MCT-22-0262.
Mol Cancer Ther. 2023.
PMID: 36399631
Free PMC article.